Touch Bionics |
Touch Bionics brought the i-LIMB Hand to market, a first-to-market prosthetic device with five individually powered articulating digits. The company continues to develop leading-edge technologies for the treatment of patients with upper-limb deficiencies.In early 2003, Touch Bionics, a spin-out from the NHS Scotland via Scottish Health Innovations Ltd (SHIL) was created. The company was initially called Touch EMAS, EMAS standing for Edinburgh Modular Arm System. In 2005 it was re-branded Touch Bionics to communicate the dynamism of the company’s products and the future focus of its prosthesis technology.
Touch Bionics has launched three key products, the i-LIMB Hand, ProDigits, and LIVINGSKIN. The i-LIMB Hand is the world’s first commercially available multi-articulating bionic hand. It has five independently powered digits that open and close around objects. It supports amputees in going about their everyday lives. In medicine, bionics means the replacement or enhancement of organs or other body parts by mechanical means. more ProDigits, short for Prosthetic Digits, are the self-contained fingers that are individually powered and controlled to provide new fingers for partial hand patients with severed fingers. The i-LIMB Hand is effectively a chassis for five ProDigits. Individual ProDigits are used for patients who have lost part of their hand or a whole finger or fingers. LIVINGSKIN, is a unique and lifelike prosthetic skin that Touch Bionics supplies with the i-LIMB hand. An aesthetic restoration solution that is a high-definition silicone prosthesis created to resemble human skin by mimicking the three dermal layers of natural human skin. To ensure proper color matching and fit, every prosthesis is custom crafted for each individual. LIVINGSKIN prostheses can be created and fitted for any level of finger, hand, arm or lower limb amputation. SHIL Chairman Peter Shakeshaft said, “We are delighted that this world-breaking technology which emanated from NHS Scotland has reached this important milestone of commercial acceptance. Touch Bionics was our first spin-out company and it is pleasing to have been able to support the technology phase and for NHS Scotland and David Gow, the inventor, to benefit from such an important global invention. Such support is the very essence of SHIL’s existence and this early success confirms the rationale behind the decision to create SHIL.” For further information about Touch Bionics please contact: Stuart Mead (CEO) Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Telephone: +44 (0)01506 438556 Website: www.touchbionics.com Or Sandy Allan at Scottish Health Innovations Ltd. |